Department of Cardiology, Thoraxcentre, Room Ba-585, Erasmus University Medical Centre, 'S-Gravendijkwal 230, 3015, Rotterdam, GE, The Netherlands,
Neth Heart J. 2015 Mar;23(3):153-60. doi: 10.1007/s12471-015-0652-2.
Drug-eluting stents (DES) are widely used as first choice devices in percutaneous coronary interventions. However, certain concerns are associated with the use of DES, i.e. delayed arterial healing with a subsequent risk of neo-atherosclerosis, late stent thrombosis and hypersensitivity reactions to the DES polymer. Bioresorbable vascular scaffolds are the next step in percutaneous coronary interventions introducing the concept of supporting the natural healing process following initial intervention without leaving any foreign body materials resulting in late adverse events. The first-generation devices have shown encouraging results in multiple studies of selected patients up to the point of full bioresorption, supporting the introduction in regular patient care. During its introduction in daily clinical practice outside the previously selected patient groups, a careful approach should be followed in which outcome is continuously monitored.
药物洗脱支架（DES）被广泛用作经皮冠状动脉介入治疗的首选器械。然而，DES 的使用存在一些问题，即动脉愈合延迟，随后发生新生动脉粥样硬化、晚期支架血栓形成和对 DES 聚合物的过敏反应。生物可吸收血管支架是经皮冠状动脉介入治疗的下一步，它引入了在初始干预后支持自然愈合过程而不留下任何异物材料的概念，从而导致晚期不良事件。第一代设备在多项针对特定患者的研究中取得了令人鼓舞的结果，直至完全生物吸收，支持将其引入常规患者护理中。在之前选择的患者群体之外，将其引入日常临床实践中时，应采取谨慎的方法，不断监测结果。
